At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

China’s WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to US drug maker Merck & Co for about US$500 million, ahead of potential US legislation that would restrict ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation ...

WuXi Biologics agreed to sell an overseas vaccine facility to Merck & Co. for half a billion dollars, a move that could strengthen the company's cash flow and margins as it navigates global ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

Merck's €500 million investment in Dundalk adds to €3 billion invested in Ireland over three years. Approximately 1,000 new jobs planned, including 150 at the Dundalk facility. The $520.1 ...

With potential passage of the BIOSECURE Act looming and WuXi Biologics seeing its share price and profits decline, the Chinese biopharma contract manufacturing giant is responding with a sizable ...